

Supplementary Table 5. Univariate logistic regression analysis for complete end-treatment response and sustained virologic response at 12 weeks after treatment

Variable	P-value	OR	95% CI
Age (years)	0.936	0.999	0.968, 1.031
Male sex	0.882	1.069	0.442, 2.584
Body mass index (kg/m ²)	0.679	1.034	0.883, 1.21
Liver cirrhosis	0.077	0.445	0.181, 1.091
IFN-experienced	0.997	Too high	<0.001, –
AST (IU/L)			
Baseline	0.323	0.996	0.99, 1.003
4 weeks	0.667	0.997	0.983, 1.011
EOT	0.008	0.969	0.946, 0.992
AST >41 IU/L			
Baseline	0.254	0.555	0.201, 1.528
4 weeks	0.460	0.682	0.247, 1.882
EOT	0.203	0.517	0.187, 1.426
ALT (IU/L)			
Baseline	0.832	1.001	0.994, 1.008
4 weeks	0.975	1.000	0.985, 1.015
EOT	0.097	0.984	0.965, 1.003
ALT >41 IU/L			
Baseline	0.559	1.331	0.51, 3.47
4 weeks	0.980	0.987	0.358, 2.722
EOT	0.842	0.894	0.298, 2.681
Bilirubin (mg/dL)			
Baseline	0.519	0.873	0.578, 1.319
4 weeks	0.001	0.403	0.239, 0.68
EOT	0.009	0.501	0.299, 0.84
Bilirubin >2.0 mg/dL			
Baseline	0.519	0.873	0.578, 1.319
4 weeks	0.001	0.403	0.239, 0.68
EOT	0.009	0.501	0.299, 0.84
Albumin (g/dL)			
Baseline	0.059	2.030	0.974, 4.23
4 weeks	0.006	3.116	1.389, 6.993
EOT	0.114	1.965	0.85, 4.544
Albumin <3.5 g/dL			
Baseline	0.584	0.709	0.207, 2.427
4 weeks	0.020	0.270	0.09, 0.813
EOT	0.068	0.317	0.092, 1.087
PT (INR)			
Baseline	0.311	0.415	0.076, 2.279
4 weeks	0.141	0.205	0.025, 1.691
EOT	0.394	0.401	0.049, 3.277

Supplementary Table 5. Continued

Variable	P-value	OR	95% CI
Platelet count (/mm ³)			
Baseline	0.015	1.009	1.002, 1.016
4 weeks	0.043	1.007	1, 1.015
EOT	0.024	1.009	1.001, 1.016
Platelet count <150/mm ³			
Baseline	0.173	0.527	0.21, 1.324
4 weeks	0.042	0.400	0.166, 0.969
EOT	0.083	0.453	0.185, 1.11
APRI			
Baseline	0.420	0.978	0.927, 1.032
4 weeks	0.110	0.703	0.456, 1.084
EOT	<0.001	0.176	0.08, 0.387
APRI >0.7			
Baseline	0.228	0.576	0.235, 1.412
4 weeks	<0.001	0.206	0.085, 0.499
EOT	0.005	0.255	0.098, 0.667
APRI >1.0			
Baseline	0.214	0.571	0.236, 1.381
4 weeks	0.001	0.185	0.067, 0.513
EOT	<0.001	0.127	0.042, 0.384
FIB-4			
Baseline	0.098	0.972	0.939, 1.005
4 weeks	0.017	0.831	0.714, 0.968
EOT	<0.001	0.564	0.424, 0.75
FIB-4 ≥1.45			
Baseline	0.270	0.565	0.205, 1.557
4 weeks	0.216	0.568	0.232, 1.391
EOT	0.061	0.415	0.165, 1.041
FIB-4 ≥3.25			
Baseline	0.014	0.326	0.133, 0.801
4 weeks	<0.001	0.173	0.066, 0.452
EOT	0.005	0.209	0.069, 0.631
Baseline HCV RNA (IU/mL)			
>6,000,000 IU/mL	0.118	0.735	0.499, 1.082
>1,120,000 IU/mL	0.361	0.623	0.226, 1.718
>1,120,000 IU/mL	0.077	0.445	0.182, 1.091
LS*, baseline (kPa)			
F4 (>12.8 kPa)	<0.001	0.947	0.921, 0.974
F4 (>12.8 kPa)	0.064	0.428	0.175, 1.05
F3–F4 (>9.6 kPa)	0.058	0.426	0.176, 1.029
F2–F4 (>8.4 kPa)	0.226	0.575	0.235, 1.408
Rapid virologic response	0.974	Too high	<0.001, –

OR, odds ratio; CI, confidence interval; IFN, interferon; AST, aspartate aminotransferase; EOT, end of treatment; ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalized ratio; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis-4; HCV, hepatitis C virus; LS, liver stiffness.

*Measured by transient elastography.